Martin Auster Analyst Performance

Managing Director Biotechnology at Raymond James Financial

Martin Auster is a stock analyst at Raymond James Financial focused in the medical sector, covering 19 publicly traded companies. Over the past year, Martin Auster has issued 22 stock ratings, including strong buy, buy, and hold recommendations. While full access to Martin Auster's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Martin Auster's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 48 Last 7 Years
Buy Recommendations: 71.74% 33 Buy Ratings
Companies Covered: 19 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	28.3%	12 ratings
Buy	43.5%	20 ratings
Hold	23.9%	11 ratings
Sell	4.3%	2 ratings

Out of 46 total stock ratings issued by Martin Auster at Raymond James Financial, the majority (43.5%) have been Buy recommendations, followed by 28.3% Strong Buy, 23.9% Hold, and 4.3% Sell.

Best & Worst Calls

Best Call
000.0%
PTCT
Jan 2019
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
ANAB
Nov 2018
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	94.7% of companies on NASDAQ	18 companies
NYSE	5.3% of companies on NYSE	1 company

Martin Auster, an analyst at Raymond James Financial, currently covers 19 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 18 companies	94.7%
	Manufacturing 1 company	5.3%

Martin Auster of Raymond James Financial specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 14 companies	73.7%
MED - DRUGS 3 companies	15.8%
MED - GENERIC DRG 1 company	5.3%
Miscellaneous 1 company	5.3%

About Martin Auster

Martin Auster joined Raymond James in 2025 and covers the biotechnology industry. Previously, he served as chief financial officer at Ventyx biosciences from 2021-2024 and was a research analyst at UBS Securities LLC from 2016-2017 and at Credit Suisse Securities (USA) LLC from 2017-2021. Prior to that, Dr. Auster held the positions of chief business officer at Ascendis Pharma from 2014- 2016 and VP-business development & strategic finance at United Therapeutics Corp. from 2009-2014. Earlier in his career, he served as a senior equity analyst at Truist Securities, Inc., as a senior biotechnology analyst at Wachovia Securities LLC, and as a portfolio manager at GLG Partners, Inc. Dr. Auster completed his undergraduate degree at the University of Michigan and obtained a doctorate from the University of Texas Medical Branch at Galveston.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
EQ Equillium	4/13/2026	Initiated Coverage	$1.70	$6.00	Strong-Buy
SYRE Spyre Therapeutics	4/13/2026	Initiated Coverage	$63.27	$80.00	Strong-Buy
EWTX Edgewise Therapeutics	3/10/2026	Set Price Target	$29.74	$46.00
BBIO BridgeBio Pharma	2/12/2026	Set Price Target	$77.68	$89.00	Outperform
IRON Disc Medicine	1/15/2026	Reiterated Rating	$71.58		Market Perform
ALNY Alnylam Pharmaceuticals	1/12/2026	Reiterated Rating	$398.29	$472.00	Outperform
EVMN Evommune	1/7/2026	Initiated Coverage	$16.22	$40.00	Strong-Buy
EVMN Evommune	1/7/2026	Initiated Coverage	$16.22	$40.00	Strong-Buy
SEPN Septerna	12/19/2025	Initiated Coverage	$27.54	$38.00	Strong-Buy
SEPN Septerna	12/19/2025	Initiated Coverage	$29.58	$38.00	Strong-Buy
PHAT Phathom Pharmaceuticals	12/11/2025	Initiated Coverage	$14.57	$28.00	Strong-Buy
PHAT Phathom Pharmaceuticals	12/11/2025	Initiated Coverage	$14.56	$28.00	Strong-Buy
IRON Disc Medicine	12/8/2025	Reiterated Rating	$96.38	$117.00	Strong-Buy
BBIO BridgeBio Pharma	10/30/2025	Reiterated Rating	$64.16	$71.00	Outperform
RNA Avidity Biosciences	10/27/2025	Downgrade	$49.15		Market Perform
BBIO BridgeBio Pharma	10/21/2025	Boost Price Target	$54.90	$59.00	Outperform
IRON Disc Medicine	10/17/2025	Boost Price Target	$92.36	$108.00	Strong-Buy
ASND Ascendis Pharma A/S	10/17/2025	Initiated Coverage	$207.03	$271.00	Strong-Buy
ASND Ascendis Pharma A/S	10/16/2025	Upgrade	$210.50		Strong-Buy
DYN Dyne Therapeutics	8/25/2025	Upgrade	$12.58	$35.00	Strong-Buy
ALNY Alnylam Pharmaceuticals	7/30/2025	Initiated Coverage	$330.55	$370.00	Outperform
DYN Dyne Therapeutics	7/29/2025	Reiterated Rating	$9.14	$31.00	Outperform

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.